13R FATE

Expecting a 13R move here.

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biotechnology company specializing in induced pluripotent stem cell (iPSC) technology to develop cellular immunotherapies for cancer and immune disorders. Below are its key fundamentals:

Financial Overview:
Revenue: 3.1M in Q3 2024, primarily from preclinical development collaborations.
Net Loss: 134M in the first three quarters of 2024, reflecting high R&D and administrative expenses.
Cash Position: 297M as of September 2024, with no debt and a cash runway of 2.2 years.
Operating Expenses: 55.5M in Q3 2024, including 34.7M for R&D and 20.8M for general administration.


Key Metrics:
Market Cap: Approximately 191M
Debt-to-Equity Ratio: 0%, indicating no leverage.
Cash Per Share: $5.86, making it an attractive takeover target.
Institutional Ownership: Over 98% of shares.
Challenges:
Declining Revenue: Revenue dropped significantly year-over-year due to reduced collaboration income.
High Cash Burn: Burn rate of 133M annually, though reduced by 28% compared to the previous year.
Speculative Risks: High volatility and likelihood of financial distress within two years.

Outlook:
Fate Therapeutics is focused on advancing its iPSC-based pipeline but faces financial pressure due to declining revenue and ongoing losses. Its strong cash position provides a temporary cushion, but long-term viability depends on successful clinical progress and partnerships.